Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Other Working Capital Changes (2021 - 2025)

Krystal Biotech's Other Working Capital Changes history spans 5 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 64.71% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $2.3 million, down 68.87%, while the annual FY2025 figure was $2.3 million, 68.87% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was $1.9 million at Krystal Biotech, up from -$973000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $5.3 million in Q4 2024 and bottomed at -$973000.0 in Q3 2025.
  • The 5-year median for Other Working Capital Changes is $235000.0 (2022), against an average of $525200.0.
  • The largest annual shift saw Other Working Capital Changes crashed 6933.33% in 2022 before it soared 1967.86% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at $1.7 million in 2021, then tumbled by 85.08% to $258000.0 in 2022, then rose by 13.95% to $294000.0 in 2023, then soared by 1707.14% to $5.3 million in 2024, then tumbled by 64.71% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Other Working Capital Changes are $1.9 million (Q4 2025), -$973000.0 (Q3 2025), and $834000.0 (Q2 2025).